TMCnet News

Research and Markets: The Latest Sales Figures in Oncology Drug Pipeline Update 2014
[September 02, 2014]

Research and Markets: The Latest Sales Figures in Oncology Drug Pipeline Update 2014


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/7kh8nd/the_latest_sales) has announced the addition of the "The Latest Sales Figures in Oncology Drug Pipeline Update 2014" report to their offering.

The Latest Sales Figures in Oncology brings together up to 5 years of sales data on top 70+ cancer drugs by country/region from both global pharmaceutical companies to progressive biotech companies. The analysis leverages the power of the author's 1st Oncology intelligence which combines company disclosed product sales and detailed drug development information. The results is not only a unique insight into the developmental positioning of each marketed drugs but together they also tell us how they will continue to change the competitive landscape and with what force.

There are today 32 companies plus partners developing 70 The Latest Sales Figures in Oncology drugs in 836 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 18 drugs. The Latest Sales Figures In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 83 different targets. All included targets have been cross-referenced for the presence of mutations associated wit human cancer.



To date 80 out of the 82 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 27 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs


  • Marketed# 61
  • Pre-registration# 2
  • Phase III# 38
  • Phase II# 57
  • Phase I# 40
  • Preclinical# 2
  • No Data# 3
  • Suspended# 2
  • Ceased# 18

Identified drugs are linked to more than 83 different targets, divided into 27 classifications of molecular function:

  • Acid phosphatase activity
  • ATPase activity
  • Catalytic activity
  • Deaminase activity
  • DNA topoisomerase activity
  • DNA-methyltransferase activity
  • G-protein coupled receptor activity
  • Growth factor activity
  • Hydrolase activity
  • Isomerase activity
  • Kinase activity
  • Ligand-dependent nuclear receptor activity
  • Ligase activity
  • Molecular function unknown
  • Oxidoreductase activity
  • Protein binding
  • Protein serine/threonine kinase activity
  • Protein threonine/tyrosine kinase activity
  • Protein-tyrosine kinase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • Structural constituent of cytoskeleton
  • Transcription factor activity
  • Transcription regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity

Sub-Cellular Localization: Identified targets are categorized into 18 different primary and alternate sub-cellular localizations:

  • Chromosome
  • Clathrin-coated vesicle
  • Cytoplasm
  • Cytoplasmic vesicle
  • Cytosol
  • Endoplasmic reticulum
  • Endosome
  • Extracellular
  • Integral to membrane
  • Kinetochore
  • Lysosome
  • Mitochondrion
  • Nucleolus
  • Nucleus
  • Perinuclear region
  • Perinuclear vesicle
  • Plasma membrane
  • Sarcoplasmic reticulum

For more information visit http://www.researchandmarkets.com/research/7kh8nd/the_latest_sales


[ Back To TMCnet.com's Homepage ]